How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,785 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1741. Follicular mucinosis, mycosis fungoides, and acute myeloid leukemia. Full Text available with Trip Pro

Follicular mucinosis, mycosis fungoides, and acute myeloid leukemia. 2341572 1990 06 25 2018 11 13 0021-9746 43 4 1990 Apr Journal of clinical pathology J. Clin. Pathol. Follicular mucinosis, mycosis fungoides, and acute myeloid leukemia. 347 Habboush H W HW Lucie N P NP Mackie R M RM Ashworth J J Turbitt M M eng Case Reports Letter England J Clin Pathol 0376601 0021-9746 AIM IM Hair Diseases complications Humans Leukemia, Myeloid, Acute etiology Male Middle Aged Mycosis Fungoides complications

1990 Journal of Clinical Pathology

1742. Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides. Full Text available with Trip Pro

Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides. 2503190 1989 09 15 2018 11 13 0959-8138 298 6689 1989 Jun 24 BMJ (Clinical research ed.) BMJ Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides. 1713 Braathen L R LR Stavem P P eng Case Reports Journal Article England BMJ 8900488 0959-8138 0 Interferon Type I 0 Recombinant Proteins AIM IM Anemia, Hemolytic, Autoimmune chemically induced Humans (...) Interferon Type I adverse effects Male Middle Aged Mycosis Fungoides drug therapy Recombinant Proteins Skin Neoplasms drug therapy 1989 6 24 1989 6 24 0 1 1989 6 24 0 0 ppublish 2503190 PMC1836763 Br J Dermatol. 1983 Jul;109(1):49-56 6860571 Clin Exp Immunol. 1983 Oct;54(1):1-13 6193915 Br J Dermatol. 1984 Apr;110(4):495-7 6608954 Ann Intern Med. 1984 Oct;101(4):484-7 6332565 Ann Intern Med. 1986 Aug;105(2):306 3729223 Lancet. 1985 Jul 13;2(8446):100-1 2861513 JAMA. 1985 Sep 13;254(10):1353-4 4021013

1989 BMJ : British Medical Journal

1743. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Full Text available with Trip Pro

Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Patterns of mycosis fungoides incidence and associated mortality in the United States were evaluated.Data were taken from the Surveillance, Epidemiology, and End Results cancer registry program and the National Center for Health Statistics.The incidence rate from 1973 through 1992 was 0.36/10(5) person-years. The age-adjusted incidence rate ratio of Blacks to Whites was 1.7; that of Asians to Whites (...) was 0.6. There was no evidence of increasing incidence rates during the period 1983 through 1992. Mortality rates declined steadily from 1979 to 1991 and were less heterogeneous geographically than incidence rates. Mortality rate patterns with age, sex, and race were similar to the corresponding incidence patterns.The incidence rate of mycosis fungoides has stabilized and the mortality rate has declined. For unknown reasons, the disorder varies greatly among demographic and geographic subgroups.

1999 American Journal of Public Health

1744. Expression of Cytotoxic Proteins by Neoplastic T Cells in Mycosis Fungoides Increases with Progression from Plaque Stage to Tumor Stage Disease Full Text available with Trip Pro

Expression of Cytotoxic Proteins by Neoplastic T Cells in Mycosis Fungoides Increases with Progression from Plaque Stage to Tumor Stage Disease Granzyme B (GrB) and T-cell-restricted intracellular antigen (TIA-1) are cytotoxic proteins that are specifically expressed by cytotoxic CD4 or CD8 positive T cells and natural killer cells. Recent studies demonstrated frequent expression of GrB and TIA-1 by neoplastic cells in primary cutaneous CD30(+) large T-cell lymphomas and lymphomatoid papulosis (...) but not in CD30(-) large T-cell lymphomas. In the present study, 74 biopsies from 54 patients with mycosis fungoides (MF) were investigated for the expression of GrB and TIA-1 using immunohistochemistry on paraffin sections. Staining of more than 10% of the neoplastic T cells for GrB or TIA-1 was considered positive. All but two follow-up biopsies had been obtained from patients without extracutaneous disease at the time of biopsy. Expression of TIA-1 and GrB was found in 33 (45%) and 14 (19%) of 74 MF

1999 The American journal of pathology

1745. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. Full Text available with Trip Pro

Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. We analyzed the expression of 13 chemokine receptors in mycosis fungoides, in order to assess the contribution of chemotaxis to the pathogenesis of the disease. Material from skin biopsies of six patients with early disease and six patients at the tumor stage of mycosis fungoides was analyzed by immunohistochemistry and partly also by flow cytometry. The receptors CCR1, CCR2 (...) , CCR3, CCR5, CCR6, CXCR1, CXCR2, CXCR5, and CX3CR1 were rarely and inconsistently detected in lesional skin and thus their participation in mycosis fungoides could largely be ruled out. In contrast, CCR4, CXCR3, and CXCR4 were substantially expressed on both mycosis fungoides cells and the surrounding reactive T cells in the early patch and plaque stages of the disease, indicating an involvement of these chemokine receptors in the disease process. In the tumor stage of mycosis fungoides, we

2003 Journal of Investigative Dermatology

1746. Correlations between clinical, histologic, blood, and skin polymerase chain reaction outcome in patients treated for mycosis fungoides. Full Text available with Trip Pro

Correlations between clinical, histologic, blood, and skin polymerase chain reaction outcome in patients treated for mycosis fungoides. Little information is currently available regarding post-treatment outcome of TCR-targeted PCR in skin and/or peripheral blood in patients with Mycosis Fungoides (MF) when a dominant gene rearrangement is present at time of diagnosis. To address this matter, a study evaluating the correlations between post-treatment clinical, histological, blood and skin PCR

2003 Journal of Investigative Dermatology

1747. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. Full Text available with Trip Pro

Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. Fifty-one mycosis fungoides samples were analyzed for microsatellite instability (MSI) using the panel of markers recommended for hereditary nonpolyposis colorectal cancer kindred and a panel we designed for cutaneous T cell lymphoma in order to compare detection rates and determine if MSI is a genome-wide phenomenon. Samples demonstrating MSI were analyzed (...) expression was studied using immunohistochemical techniques. Five of nine patients with MSI and hMLH1 promoter methylation showed abnormal hMLH1 protein expression with normal hMSH2 gene expression. All other patients tested demonstrated normal hMLH1 and hMSH2 protein expression. MSI was found to be more prevalent in tumor stage mycosis fungoides (47%) than early stage disease (20%) and was associated with an older age of onset of mycosis fungoides. MSI may be a consequence of hMLH1 promoter

2003 Journal of Investigative Dermatology

1748. Density of neoplastic lymphoid infiltrate, CD8+ T cells, and CD1a+ dendritic cells in mycosis fungoides. Full Text available with Trip Pro

Density of neoplastic lymphoid infiltrate, CD8+ T cells, and CD1a+ dendritic cells in mycosis fungoides. CD8+ T cells and epidermal/dermal dendritic cells expressing CD1a are found among neoplastic CD4+ T cells in mycosis fungoides (MF) lesions. This study analysed the relation of CD8+ tumour infiltrating lymphocytes (TILs), CD1a+ epidermal Langerhan's cells (LCs), and dermal dendritic cells (DDCs) to clinicopathological parameters in 46 MF cases.Pretreatment diagnostic biopsy specimens of 46

2003 Journal of Clinical Pathology

1749. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. (Abstract)

Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Mycosis fungoides (MF) is predominantly a disease of older patients, but occasionally occurs in children. The aims of the current study were to describe the clinical presentation, pathologic features, and disease progression (DP) in patients who developed MF before age 16 years.A retrospective study was performed. Patients with juvenile-onset MF were identified from our databases

2003 Cancer

1750. Cold urticaria in a patient with mycosis fungoides. (Abstract)

Cold urticaria in a patient with mycosis fungoides. We report what we believe to be the first documentation of a patient with both cold urticaria and mycosis fungoides. The patient described a marked worsening of his long-standing lesions of mycosis fungoides at the same time as the onset of cold sensitivity. We believe this suggests a possible association between these 2 rare diseases.

2002 Journal of American Academy of Dermatology

1751. Increased serum immunoglobulin levels are common in mycosis fungoides and Sezary syndrome. (Abstract)

Increased serum immunoglobulin levels are common in mycosis fungoides and Sezary syndrome. Patients with cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] and Sézary syndrome [SS]) acquire immunodeficiency and opportunistic infections.We attempted to determine whether abnormalities of humoral immunoglobulin levels are present.A retrospective analysis of serum immunoglobulin levels in patients with CTCL at baseline evaluation at a cancer center was compared to levels in patients

2002 Journal of American Academy of Dermatology

1752. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. (Abstract)

Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. Radiotherapy has been successfully implemented in the treatment of mycosis fungoides (MF) for almost a century. With the development of the modern linear accelerator, it has become possible to treat extended areas of the skin with accelerated electrons. Total skin electron beam radiation (TSEB) has been in use

2002 Journal of American Academy of Dermatology

1753. Mycosis fungoides: the great imitator. Full Text available with Trip Pro

Mycosis fungoides: the great imitator. A considerable number of reports have documented mycosis fungoides (MF) mimicking other dermatoses, but a comprehensive review has not been published. Our aim was to comprehensively review reports of various dermatoses simulated by MF. Additionally, 2 cases in which MF simulated diseases not previously documented (psoriasis and erythema annulare centrifugum) are presented. A literature search of all case reports of MF cited in the MEDLINE database from

2002 Journal of American Academy of Dermatology

1754. Treatment of childhood mycosis fungoides with topical PUVA. (Abstract)

Treatment of childhood mycosis fungoides with topical PUVA. Mycosis fungoides is the most common type of cutaneous T-cell lymphoma, which is usually observed in mid to late adulthood. We report 5 cases of mycosis fungoides in children, all presenting as patch- and plaque-stage disease most commonly involving the buttocks. Histologic examination showed in every case the typical features of mycosis fungoides. In 4 of the 5 cases, the infiltrating lymphocytes were characterized by the T-cell (...) phenotype CD3(+), CD4(+), CD8(+); and in 3 cases, a monoclonal rearrangement of the T-cell receptor gamma (TCR-gamma) gene was found. Three children received topical PUVA treatment, and the other two were treated with mid-potency topical corticosteroids, resulting in complete clinical remission. A management approach to mycosis fungoides with topical PUVA may be appropriate for children.

2002 Journal of American Academy of Dermatology

1755. Clinicopathologic reassessment of non-mycosis fungoides primary cutaneous lymphomas during 17 years. (Abstract)

Clinicopathologic reassessment of non-mycosis fungoides primary cutaneous lymphomas during 17 years. New classification systems have recently been proposed for primary cutaneous lymphomas (PCLs). The aim of our study was to evaluate the applicability and significance of the new classification systems to the diagnosis and management of non-mycosis fungoides (non-MF) PCL.Immunohistochemical restaining, histological reclassification, and clinical follow-up of all new non-MF PCL cases during 17

2002 International Journal of Dermatology

1756. Long-term control of mycosis fungoides of the hands with topical bexarotene. (Abstract)

Long-term control of mycosis fungoides of the hands with topical bexarotene. Limited Stage IA mycosis fungoides (MF) is often treated with topical steroids, which can cause atrophy, or with nitrogen mustard, which imposes several limitations on the patient's lifestyle. Topical bexarotene is a novel synthetic rexinoid with few side-effects that has shown efficacy for treatment of mycosis fungoides skin lesions in recent Phase II-III clinical trials. The Phase I-II trial involving 67 stage IA-IIA (...) MF patients demonstrated complete response (CR) in 21% and partial response (PR) in 42% of the patients. The median time to response was approximately 20 weeks. In the phase III trial of refractory stage IA, IB and IIA MF, the patients demonstrated a 44% response rate (8% CR). Patients with no prior therapy for mycosis fungoides responded at a higher rate (75%) than those with prior topical therapies.Case report of a patient with MF limited to the hands treated with topical bexarotene 0.1% gel

2003 International Journal of Dermatology

1757. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. (Abstract)

Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. The increased risk of second malignancies, including nonmelanoma skin cancers, in cutaneous T-cell lymphoma (CTCL) patients has been well documented. However, relatively few studies of malignant melanoma in CTCL patients have been reported.A database of 250 CTCL patients registered over a 3-year period was searched to identify patients with diagnoses of both mycosis fungoides (MF) and malignant melanoma.We (...) to the histologic confirmation of melanoma. Six patients had early stages of MF (IA or IB), while one patient presented with simultaneous erythrodermic mycosis fungoides involving the lymph nodes as well as melanoma metastatic to the lymph nodes from an unknown primary.There is an elevated prevalence of malignant melanoma in MF patients compared to the general US population (P < 0.00001) with a relative risk of 15.3 for observing malignant melanoma in MF patients (95% confidence interval 7.0-33.8). Possible

2003 International Journal of Dermatology

1758. Assessment of histologic criteria in the diagnosis of mycosis fungoides. (Abstract)

Assessment of histologic criteria in the diagnosis of mycosis fungoides. The histologic diagnosis of early mycosis fungoides (MF) can be difficult to establish in many instances because the subtle changes observed in patches of MF are also present in many inflammatory dermatoses.To assess the frequency and significance of many of these histologic parameters, we retrospectively reviewed 50 slides from patients with documented MF in patch, plaque, and tumor stages. The diagnosis of MF

2003 International Journal of Dermatology

1759. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. (Abstract)

Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Imiquimod is a topical immune response modifier that binds to Toll-like receptors 7 and 8 and induces alpha-interferon. We locally applied imiquimod 5% cream (Aldara) daily for 2 weeks on a PUVA- and retinoid-resistant plaque on the face of a patient with mycosis fungoides. The diagnosis was based on clinical appearance, histology and molecular studies. Most of the disease manifestations showed a clear

2003 Dermatology

1760. Granulomatous mycosis fungoides presenting as an acquired ichthyosis. (Abstract)

Granulomatous mycosis fungoides presenting as an acquired ichthyosis. We report a case of a 69-year-old gentleman who presented with a 3-month history of unexplained fevers and malaise who developed generalized pruritus, alopecia and an ichthyosiform erythematous eruption on his forearms, legs, chest and back. Skin histology, immunophenotyping and molecular features were consistent with granulomatous mycosis fungoides. He has been successfully treated with twice weekly PUVA photochemotherapy.

2003 Clinical & Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>